Department of Urology, David Geffen School of Medicine at University of California-Los Angeles, Los Angeles, CA 90095, United States

Over the past 2 decades, a greater understanding of the basic biology and genetics of kidney cancer has occurred. Surgical techniques have also evolved, and technological advances have made possible new methods of managing renal tumors. The most extensively used system to provide prognostic information for renal cell carcinoma (RCC) is currently the tumor, nodes, metastasis (TNM) staging system. Emerging data over the last few years has questioned whether further revisions are needed and if improvements can be made with the introduction of new, more accurate and predictive prognostic factors. The recent discovery of molecular tumor biomarkers are expected to revolutionize the staging of RCC and potentially lead to the development of new therapies based on molecular targeting. This review will examine the current staging modalities and prognostic factors associated with RCC as well as the selection of patients most likely to benefit from clinical trials.

Written by
Lam JS, Klatte T, Kim HL, Patard JJ, Breda A, Zisman A, Pantuck AJ, Figlin RA.

Reference
Crit Rev Oncol Hematol. 2007 Oct 9; [Epub ahead of print]
doi:10.1016/j.critrevonc.2007.08.003

PubMed Abstract
PMID:17931881

UroToday.com Renal Cancer Section

Please log-in or register in order to submit comments.

Powered by AkoComment!